Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ASH1L intronic transcript 1 (ASH1L-IT1) is a long non-coding RNA arising from an intronic region of the *ASH1L* gene. Unlike the canonical protein-coding ASH1L, which encodes a histone methyltransferase involved in chromatin modification, development, and diverse human diseases, little is concretely established regarding the biological function, disease associations, or therapeutic targetability of ASH1L-IT1. The term is often confused with the protein-coding ASH1L, which is itself a validated drug discovery and disease biomarker target due to its enzymatic function in chromatin biology and cancer[2][1][4]. ASH1L-IT1 is not considered a standard therapeutic target or part of any known drug-interaction pathways, and information is notably sparse and ambiguous in both the literature and databases. If you instead meant the canonical protein-coding ASH1L, clarify, as this is a well-characterized histone methyltransferase implicated in cancer, neurodevelopmental disorders, and other major roles[2][1][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ASH1L intronic transcript 1 (ASH1L-IT1).